FDA Urgency To Clear TLC Evacet May Be Lessened By Ellence Approval
Executive Summary
The impetus for FDA to approve The Liposome Company's Evacet (liposomal doxorubicin, D-99), based on incomplete efficacy data may be lessened by the recent U.S. approval of Pharmacia & Upjohn's Ellence (epirubicin).